CKD Bio Corp. (KRX: 063160)
South Korea
· Delayed Price · Currency is KRW
22,600
-350 (-1.53%)
Dec 19, 2024, 3:30 PM KST
CKD Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 - 2013 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2013 |
Operating Revenue | 159,935 | 156,042 | 142,238 | 124,600 | 137,184 | 124,510 | Upgrade
|
Other Revenue | -0 | -0 | - | - | 0 | 0 | Upgrade
|
Revenue | 159,935 | 156,042 | 142,238 | 124,600 | 137,184 | 124,510 | Upgrade
|
Revenue Growth (YoY) | 3.59% | 9.70% | 14.16% | -9.17% | 10.18% | 9.45% | Upgrade
|
Cost of Revenue | 152,985 | 139,252 | 128,932 | 96,736 | 101,010 | 101,090 | Upgrade
|
Gross Profit | 6,950 | 16,790 | 13,306 | 27,864 | 36,174 | 23,420 | Upgrade
|
Selling, General & Admin | 15,057 | 15,513 | 12,585 | 10,664 | 10,057 | 8,530 | Upgrade
|
Research & Development | 16,277 | 15,432 | 11,516 | 9,118 | 10,704 | 7,881 | Upgrade
|
Operating Expenses | 32,007 | 31,600 | 24,738 | 20,257 | 20,761 | 16,411 | Upgrade
|
Operating Income | -25,058 | -14,810 | -11,432 | 7,607 | 15,413 | 7,009 | Upgrade
|
Interest Expense | -4,564 | -2,938 | -1,936 | -627.81 | -153.41 | -129.16 | Upgrade
|
Interest & Investment Income | 334.52 | 48.06 | 6.79 | 21.03 | 111.69 | 223.47 | Upgrade
|
Currency Exchange Gain (Loss) | 286.01 | -358.4 | 1,650 | -1,214 | 777.11 | 942.59 | Upgrade
|
Other Non Operating Income (Expenses) | 2,804 | -542.18 | -1,688 | 1,273 | -487.09 | 379.89 | Upgrade
|
EBT Excluding Unusual Items | -26,198 | -18,601 | -13,399 | 7,059 | 15,661 | 8,426 | Upgrade
|
Gain (Loss) on Sale of Investments | -776.65 | 0.18 | -0.97 | -1.59 | 19.15 | -148.26 | Upgrade
|
Gain (Loss) on Sale of Assets | 180.73 | 11.15 | 42.64 | 1.54 | -41.71 | 95.81 | Upgrade
|
Pretax Income | -26,794 | -18,590 | -13,358 | 7,059 | 15,638 | 9,295 | Upgrade
|
Income Tax Expense | -3,664 | -1,887 | -6,781 | 851.98 | 3,373 | 1,339 | Upgrade
|
Net Income | -23,130 | -16,703 | -6,577 | 6,207 | 12,265 | 7,956 | Upgrade
|
Net Income to Common | -23,130 | -16,703 | -6,577 | 6,207 | 12,265 | 7,956 | Upgrade
|
Net Income Growth | - | - | - | -49.39% | 54.16% | 12.04% | Upgrade
|
Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade
|
Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade
|
Shares Change (YoY) | -0.02% | - | 1.40% | 0.45% | -0.00% | -0.03% | Upgrade
|
EPS (Basic) | -4216.38 | -3044.61 | -1198.81 | 1147.30 | 2277.20 | 1477.21 | Upgrade
|
EPS (Diluted) | -4216.38 | -3044.61 | -1198.81 | 1147.30 | 2277.20 | 1477.21 | Upgrade
|
EPS Growth | - | - | - | -49.62% | 54.16% | 12.07% | Upgrade
|
Free Cash Flow | -22,830 | -9,404 | -26,368 | -56,835 | -30,324 | -860.71 | Upgrade
|
Free Cash Flow Per Share | -4161.70 | -1714.22 | -4806.49 | -10504.67 | -5630.22 | -159.81 | Upgrade
|
Dividend Per Share | - | - | 100.000 | 200.000 | 190.476 | 190.476 | Upgrade
|
Dividend Growth | - | - | -50.00% | 5.00% | 0% | - | Upgrade
|
Gross Margin | 4.35% | 10.76% | 9.35% | 22.36% | 26.37% | 18.81% | Upgrade
|
Operating Margin | -15.67% | -9.49% | -8.04% | 6.11% | 11.23% | 5.63% | Upgrade
|
Profit Margin | -14.46% | -10.70% | -4.62% | 4.98% | 8.94% | 6.39% | Upgrade
|
Free Cash Flow Margin | -14.27% | -6.03% | -18.54% | -45.61% | -22.10% | -0.69% | Upgrade
|
EBITDA | -7,397 | 3,128 | 5,552 | 19,842 | 25,189 | 15,965 | Upgrade
|
EBITDA Margin | -4.63% | 2.00% | 3.90% | 15.92% | 18.36% | 12.82% | Upgrade
|
D&A For EBITDA | 17,661 | 17,938 | 16,984 | 12,235 | 9,777 | 8,956 | Upgrade
|
EBIT | -25,058 | -14,810 | -11,432 | 7,607 | 15,413 | 7,009 | Upgrade
|
EBIT Margin | -15.67% | -9.49% | -8.04% | 6.11% | 11.23% | 5.63% | Upgrade
|
Effective Tax Rate | - | - | - | 12.07% | 21.57% | 14.40% | Upgrade
|
Advertising Expenses | - | 163.72 | 42.48 | 12.66 | 239.71 | 249.69 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.